This study focuses on patients with Locally Advanced Rectal Cancer (LARC) who have specific genetic characteristics described as pMMR/MSS or MSI-Low. The study compares two different treatment approaches after patients have completed standard chemoradiation therapy. Both treatment groups will receive XELOX, which is a combination of chemotherapy medications, but one group will also receive an additional medication called dostarlimab (also known as JEMPERLI).
The purpose of this research is to determine how well patients respond to treatment by examining whether there are any remaining cancer cells after the therapy is completed. Dostarlimab is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The medication belongs to a group of drugs that help the body’s immune system fight cancer cells.
During the study, patients will receive treatment for up to 60 months. The treatment includes regular medical check-ups to monitor the patient’s health and response to therapy. Doctors will use various imaging techniques to check how well the treatment is working and to ensure the safety of the participants. The effectiveness of the treatment will be evaluated both through physical examinations and imaging tests.
Italy 
